1319-0164

Saudi Pharmaceutical Journal

Springer-Verlag

View prefix report (10.1007)

Health Score

0 Fair

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 93 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact93 DOIs
2

Attach ORCID iDs across 65 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact65 DOIs
3

Deposit reference lists for 6 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact6 DOIs

DOIs for this ISSN

Showing the top 5 of 94 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 AI-powered in silico twins: redefining precision medicine th… (10.1007/s44446-025-00055-x)
Abstract ORCID
57.31 13
2 Exosomes derived from umbilical cord blood NK cells inhibit… (10.1007/s44446-025-00009-3)
Abstract ORCID
45.15 7
3 Facile indazole-endowed thiadiazole hybrid derivatives as an… (10.1007/s44446-025-00003-9)
Abstract
31.97 18
4 Cannabidiol as an immune modulator: A comprehensive review (10.1007/s44446-025-00005-7)
Abstract
31.97 18
5 A comparative analysis of student perceptions on the effecti… (10.1007/s44446-025-00015-5)
Abstract ORCID
30.10 3
6 GLP-1 receptor agonism: a transformative approach for managi… (10.1007/s44446-025-00038-y)
Abstract
30.10 15
7 Curcumin inhibits IFN-γ induced PD-L1 expression via reducti… (10.1007/s44446-025-00018-2)
Abstract
26.03 10
8 Innovative approaches for beetroot (Beta Vulgaris L.) aqueou… (10.1007/s44446-025-00008-4)
Abstract ORCID
23.86 2
9 Exploring chemical constituents and anti-inflammatory mechan… (10.1007/s44446-025-00012-8)
Abstract ORCID
23.86 2
10 Leveraging MobileNetV2 and deep learning innovation for high… (10.1007/s44446-025-00019-1)
Abstract ORCID
23.86 2
11 Non-coding RNA-mediated gene regulation in Alzheimer's disea… (10.1007/s44446-025-00026-2)
Abstract
22.58 7
12 Inhalable nanoparticle-based drug delivery system for non-sm… (10.1007/s44446-025-00046-y)
Abstract
21.13 6
13 Molecular mechanisms attributed to colistin renal proximal t… (10.1007/s44446-025-00049-9)
Abstract
21.13 6
14 Excipients in pharmaceuticals: mechanisms of hypersensitivit… (10.1007/s44446-025-00004-8)
Abstract
17.47 4
15 Polyphenolic profile, hepatoprotective evaluation, and molec… (10.1007/s44446-025-00017-3)
ORCID
17.47 4
16 Towards standardized skin testing for drug-induced allergic… (10.1007/s44446-025-00031-5)
Abstract
17.47 4
17 Talazoparib and radiation enhance the senolytic efficacy of… (10.1007/s44446-025-00034-2)
Abstract
17.47 4
18 Targeting the PI3K/AKT/mTOR signaling pathway in prostate ca… (10.1007/s44446-025-00056-w)
Abstract
17.47 4
19 Arabic version of the patient education materials assessment… (10.1007/s44446-025-00013-7)
Abstract
15.05 3
20 Comparison of ileus risk in selected second-generation antip… (10.1007/s44446-025-00020-8)
Abstract ORCID
15.05 1
21 Emerging for non-invasive heparin delivery systems: recent a… (10.1007/s44446-025-00022-6)
Abstract
15.05 3
22 Evaluation of the impact of Roclaglamide on MDA-MB-231 human… (10.1007/s44446-025-00023-5)
Abstract ORCID
15.05 1
23 Prevalence, toxin virulence genes and investigating the effe… (10.1007/s44446-025-00033-3)
Abstract ORCID
15.05 1
24 Baicalin nano-micelles for dry eye disease: LC–MS/MS method… (10.1007/s44446-025-00037-z)
Abstract ORCID
15.05 1
25 Impact of coverage of drug availability regulations across t… (10.1007/s44446-025-00045-z)
Abstract ORCID
15.05 1
26 Assessment of knowledge and awareness about ovarian cancer a… (10.1007/s44446-025-00002-w)
Abstract
11.93 2
27 Design, synthesis, biological evaluation and in silico studi… (10.1007/s44446-025-00010-w)
Abstract
11.93 2
28 Assessment of prostate cancer awareness and screening knowle… (10.1007/s44446-025-00014-6)
Abstract
11.93 2
29 A Mechanistic Physiologically Based Pharmacokinetic (PBPK) m… (10.1007/s44446-025-00024-4)
Abstract
11.93 2
30 Clinical features and mortality risk in Acute Ischemic Strok… (10.1007/s44446-025-00030-6)
Abstract
11.93 2
31 Impact of CYP3A4 and CYP3A5 polymorphisms on tacrolimus dose… (10.1007/s44446-025-00035-1)
Abstract
11.93 2
32 The association between parenteral antimicrobials and bacter… (10.1007/s44446-025-00040-4)
Abstract
11.93 2
33 Polyacetylenes as antibacterial, antibiofilm, and anti-quoru… (10.1007/s44446-025-00059-7)
Abstract
11.93 2
34 Liquid crystalline system for drug delivery: structural insi… (10.1007/s44446-026-00062-6)
Abstract
11.93 2
35 Characterization of soil-derived Bacillus subtilis metabolit… (10.1007/s44446-025-00006-6)
Abstract
7.53 1
36 Neurobehavioral and molecular changes in rats exposed to eit… (10.1007/s44446-025-00007-5)
Abstract
7.53 1
37 Knowledge, attitude and practice towards anabolic–androgenic… (10.1007/s44446-025-00011-9)
Abstract
7.53 1
38 Quality assessment of some specific drug products beyond exp… (10.1007/s44446-025-00016-4)
Abstract
7.53 1
39 Evaluation of a competency-based CPD programme for pharmacis… (10.1007/s44446-025-00021-7)
Abstract
7.53 1
40 Neomycin sulfate and triamcinolone acetonide suspended ointm… (10.1007/s44446-025-00027-1)
Abstract
7.53 1
41 Engineering stable Amlodipine suspensions for flexible compo… (10.1007/s44446-025-00028-0)
Abstract
7.53 1
42 Myocarditis induced by durvalumab in a patient with hepatoce… (10.1007/s44446-025-00041-3)
Abstract
7.53 1
43 Targeting triple-negative breast cancer: apoptotic and antit… (10.1007/s44446-025-00047-x)
Abstract
7.53 1
44 Efficacy and safety of oral doxycycline for acne vulgaris tr… (10.1007/s44446-026-00066-2)
Abstract
7.53 1
45 Computational renaissance in herbal medicine: A 20-year bibl… (10.1007/s44446-026-00080-4)
Abstract
7.53 1
46 Enhancing hepatocellular carcinoma treatment: synergistic cy… (10.1007/s44446-025-00001-x)
Abstract
0.00 0
47 Spontaneous adverse drug reaction reporting: potential facil… (10.1007/s44446-025-00025-3)
0.00 1
48 Prevalence and factors associated with potentially inappropr… (10.1007/s44446-025-00029-z)
Abstract
0.00 0
49 Acidifying agents impact erlotinib and gefitinib pharmacokin… (10.1007/s44446-025-00032-4)
Abstract
0.00 0
50 Assessment of the feasibility of including community pharmac… (10.1007/s44446-025-00036-0)
0.00 0